Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma - ScienceDirect
Newly Diagnosed: D + RD Treatment | DARZALEX® IV (daratumumab)
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Maintenance Therapy with Revlimid for Multiple Myelom
Dosing and Administration for the NINLARO® (ixazomib) Regimen
Daratumumab regimen safe, effective in newly diagnosed multiple myeloma
British Journal of Haematology | Wiley Online Library
DRd Trial Design & Efficacy | REVLIMID® (lenalidomide)
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | SpringerLink
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Velcade/Revlimid/Dexamethasone New Standard for Newly Diagnosed Multiple Myeloma - CancerConnect
Tip Card: The VRd Regimen by International Myeloma Foundation - Issuu
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Optimized dosing regimens for single-agent lenalidomide in... | Download Scientific Diagram
![PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c492928e3f0ff31a9045ef665d1d8113a4831731/3-Figure1-1.png "PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar")
PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar
Tailored lenalidomide regimen benefits older patients with multiple myeloma
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial - The Lancet Haematology
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
547-Lenalidomide and dexamethasone oral | eviQ
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
